Sovaldi

Here's How Much Investing $100 In Gilead Sciences Stock Back In 2010 Would Be Worth Today

Gilead Defends Hepatitis C Treatments On Reports Of Side Effects

The 5 Top-Selling Drugs In The World

Gilead Defends Hepatitis C Treatments On Reports Of Side Effects

The 5 Top-Selling Drugs In The World

Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings

Gilead Vs. Merck: What To Know

Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings

Gilead Vs. Merck: What To Know

Gilead Trounces Hep C Estimates; Harvoni International Footprint Nearly Equals U.S.

Massachusetts Attorney General To Gilead Sciences: Cost Of Harvoni & Sovaldi Drugs 'May Constitute An Unfair Trade Practice In Violation Of Massachusetts Law'

Sovaldi Recent News

Gilead Sciences Tumbles; Unconfirmed Reports Of Drug Pricing Changes In Japan

High Drug Prices Put Gilead Under Fire From Senate Committee

Gilead Stock Whiffs, But One Pro Remains Bullish

China Rejects Gilead's Sovaldi Patent Application

Gilead Soothes Price War Worry With Q1 Results

Is Gilead Sciences About To Buy Vertex For $45 Billion?

This Data Offers Insight Into Gilead Sales

Gilead Sciences Hovering Above Major Support Level

Is Gilead's Latest Japan Win Good News For Shareholders?

Gilead Shares Tumble On Drug Warning; Baird Says Buy

Why This Analyst Thinks Gilead Sciences Will 'Handily' Beat Q4 Expectations

Gilead Sciences' Sovaldi Patent Application Rejected In India

UPDATE: Barclays Initiates Coverage On Gilead Sciences, 'Should Remain Ahead Of Its Peers'

Markets Close The Week On Negative Note As Ukraine Worries Mount

Gilead Beats Q2 Views On Revenue Growth Lead By Sovaldi Drug

Biotechs Struggling To Find A Bottom

Gilead Sciences Falls Ever-So-Slightly After Q4 Earnings Beat

Market Wrap For February 4: Investors And Traders Go Bargain Hunting